7Mar

See: https://midlandlaserclinic.co.uk/Hyperblue%20.pdf

6Mar

TREATMENT OF ACHILLES TENDINITIS WITH
CLASS IV INFRARED (980 NM) THERAPEUTIC LASER

https://www.aspenlaseru.com/wp-content/uploads/2016/07/Achilles-Tendinitis.pdf

OBJECTIVE:


To describe the clinical management of Achilles tendinitis by using a “high-power” Class IV therapeutic laser.


CLINICAL FEATURES:


This is a case of a fifty-eight year old woman, 5’4”, 155 lbs., presenting with bilateral Achilles tendon pain, the left foot for two years, the right for one year. She did not respond to physical therapy or steroid injections. Rest relieved the pain, weight bearing activity increased the pain. There was pain on palpation over her Achilles tendons. She showed decreased ankle dorsiflexion, and displayed genu valgum and foot pronation. Resisted neutral position isometric dorsiflexion and active eccentric dorsiflexion exacerbated the pain. Passive eccentric dorsiflexion did not exacerbate the pain. The patient filled out a VAS describing her “worst” pain, “best” pain, and pain “now.” This was filled out on each visit. The patient was accepted for laser therapy.


INTERVENTION AND OUTCOME:
The laser used was the class IV infrared laser, model AVI HP-7 5, continuous wave (nonpulsing). The laser emits a visible red beam at 635 nm wavelengths, and an infrared laser beam at 980 nm wavelength. The power used was 7.5 watts; the dose was 2250 joules; the area was 15 cm; the energy density was .5 w/cm2; the treatment time was 5 minutes per side and the treatment distance was 2 cm. Treatment distance was ensured by securing the laser wand stylus to maintain the treatment distance.


The stylus was kept in light contact with the patient. A swatch of cotton fabric was placed over the tendon with a 3×5 cm hole cut from it to allow for consistent laser treatment area. One open end was placed over
the Achilles insertion, and extending proximally. The patient showed significant reduction in pain as indicated by the VAS scores, and significant increase in dorsiflexion flexibility as measured after four sessions with a goniometer.


CONCLUSION:

This case demonstrates the potential benefit of conservative management for Achilles tendinitis with the utilization of “high-power” Class IV therapeutic laser technology to decrease the symptoms associated with Achilles tendinitis.

6Mar

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319951/

Abstract

Background:

Although high-intensity laser therapy (HILT) has been used for the management of musculoskeletal disorders (MSD), studies examining the effectiveness of HILT have been limited. We investigated the effectiveness of HILT in MSD using a systematic review and meta-analysis.

Methods:

We searched the ovid MEDLINE, ovid Embase, Cochrane CENTRAL library, and Web of Science until January, 2018. Relevant studies concerning the effectiveness of HILT in patients with MSD were included. Both placebo and active controls were considered as comparators and only randomized controlled trial (RCT) design studies were included. Risk of bias (ROB) was used for the quality assessment of the RCT. For continuous variables, a meta-analysis was conducted using an inverse variance random effects model. The mean difference (MD) for visual analog scale pain and standardized mean difference (SMD) for disability were applied.

Results:

Twelve studies were selected for this systematic review. In 11 studies, comprising 736 patients, pain was significantly improved by HILT compared with a control group (MD: −1.01; 95% confidence interval [CI]: −1.28 to −0.74). From the analysis of 688 patients from 10 studies, the pooled standardized mean difference (SMD) of HILT showed a significant improvement in disability scores compared with those in the control group (SMD, −1.09; 95% CI −1.77, −0.41). In subgroup analysis by treatment regions, the mean difference (MD) in neck pain was the highest at −1.02 (95% CI: −1.45, −0.58) than in controls, followed by back pain (MD, −0.91; 95% CI: −1.24, −0.59).

Conclusions:

The results of this study show that HILT treatment for back and neck pain significantly improved pain and disability scores compared with controls. The ROB of the included studies was moderate; however, significant heterogeneity existed. Thus, additional well-designed studies involving larger samples with long-term follow-up are needed to further assess each laser application, treatment region, and comparator.

6Mar

https://www.iomcworld.org/open-access/effects-of-class-iv-laser-in-knee-osteoarthritis-a-randomized-controltrial.pdf

Abstract


Background: Knee osteoarthritis (KOA) is characterized by a gradual wearing away of the cartilage in the joint through strain
originating from weight bearing, repeated injury, and/or damage and is one of the most associated causes of knee pain. Current options for pain management include medication or surgery. Consequently patients are alternatively seeking a non-invasive approach
that can help manage their pain. Recently, Class IV laser has gained popularity due to its clinical efficacy in pain management and non-invasive application.


Objective: The aim of this randomized control trial was to evaluate the effects of a 30W powered Class IV laser with 1064 nmwavelength on knee pain in the treatment of patients with KOA.
Methods: Patients were randomly assigned into two groups. Each patient underwent 7 treatment sessions every other day.
Group-I (Laser group): 30 patients were treated with a semi conductive Class IV Laser with Scanning System applicator (BTL Industries Ltd.) With a maximal power of 30 W and 1064 nm wavelength. Group-II (Control group): 30 patients were treated with the
same device without emission from the laser diode, and only a visible navigation beam to act as a placebo. All patients perception
of pain was evaluated prior to beginning treatment (baseline), following the first session, after the 7 therapies, and 1 month following
the last treatment using the Visual Analogue Scale (VAS).
Results: The Man-Whitney test revealed there was a significant (P=0.01) reduction in pain according to the VAS results for
the laser group (44.24% improvement), whereas the control group displayed no significant difference (3.93% improvement) in pain
perception following the treatment(s).


Conclusion: Class IV laser treatment was found to be an effective modality in reducing knee pain in KOA patients

3Mar

https://pubmed.ncbi.nlm.nih.gov/27119270/

Abstract

Importance: Although cutaneous warts are common lesions, full remission is not always achieved with conventional therapies. Laser modalities including carbon dioxide (CO2), erbium:yttrium-aluminum-garnet (Er:YAG), pulsed dye (PDL), and Nd:YAG have been investigated as alternative treatments for warts.

Objective: To review the use and efficacy of lasers for treating nongenital cutaneous warts.

Evidence review: Published randomized clinical trials (RCTs), cohort studies, case series, and case reports involving laser treatment of nongenital warts were retrieved by searching PubMed with no date limits. Quality ratings of studies were based on a modified version of the Oxford Centre for Evidence-Based Medicine scheme for rating individual studies. A higher emphasis was placed on RCTs and prospective cohort studies with large sample sizes and detailed methodology.

Findings: There were 35 studies published between 1989 and 2015 that comprised an aggregate of 2149 patients. Simple and recalcitrant nongenital warts treated with lasers show variable response rates (CO2 laser, 50%-100%; Er:YAG laser, 72%-100%; PDL, 47%-100%; and Nd:YAG laser, 46%-100%). Current RCTs suggest that PDL is equivalent to conventional therapies such as cryotherapy and cantharidin. Combination therapies with lasers and other agents including bleomycin, salicylic acid, and light-emitting diode have shown some success.

Conclusions and relevance: Lasers can be an effective treatment option for both simple and recalcitrant warts. The lasers most studied for this purpose are CO2, PDL, and Nd:YAG, and of these, PDL has the fewest adverse effects. Currently, use of lasers for wart treatment is limited by lack of established treatment guidelines. Future studies are needed to compare laser modalities with each other and with non-laser treatment options, and to establish optimal treatment protocols.

24Feb

This blog post explains more about the use of ESWT to treat Achilles tendinopathy and plantar fasciitis. It includes information on the benefits, risks and any alternative treatments, as well as what you can expect when you come to the podiatry clinic. If you have any further questions, please speak to the podiatrist you visit.

What are Achilles tendinopathy and plantar fasciitis?


Achilles tendinopathy is a condition that causes pain, swelling, stiffness and weakness to the Achilles tendon, which attaches your calf muscle to your heel bone. It is thought to be caused by repeated small injuries to the tendon that do not heal, and build up over time.


Plantar fasciitis is inflammation (swelling) of the plantar fascia. This is a thick fibrous band of tissue at the bottom of your foot that lies between your toes and your heel. Repeated small injuries to the plantar fascia are believed to be the cause of the inflammation.


What is ESWT?


ESWT is a procedure where shockwaves are passed through the skin to the injured part of the foot. Extracorporeal means outside of the body. The shockwaves are mechanical and not electric. They are audible, low-energy sound waves, which work by increasing blood flow to the injured area. This speeds up your body’s healing process. You will usually require a course of three to six treatments, 1-2 weeks apart.

Why should I have ESWT?


ESWT is offered to patients who have not responded well enough to other treatments, such as rest, physiotherapy, orthotics (insoles or leg braces), rest, ice therapy and pain relief. It is a minimally invasive treatment that is carried out on an outpatient basis, which means that you can go home the same day. ESWT can offer relief from pain and other symptoms.


What are the risks/side effects?


You will experience some pain/discomfort during the treatment, but you should be able to cope with this. Following the treatment, you may experience more pain, redness, bruising, swelling and numbness to the area at first. These side effects should resolve within a week, before your next treatment. Studies have shown that 5-7 out of 10 patients have found it to be effective.
There is a very small risk of tendon or ligament rupture, and damage to the soft tissue.

You must not have ESWT for Achilles tendinopathy or plantar fasciitis if you
 are pregnant
 are taking antiplatelets excluding aspirin 75mgs (for example, clopidogrel) or
anticoagulants (such as warfarin or rivaroxaban)
 have a blood clotting disorder
 are under the age of 18
 have been diagnosed with bone cancer or are being treated for active cancer
 have an infection in your foot
 have a history of Achilles tendon or plantar fascia ligament rupture
 have had a steroid injection into the affected area in the previous 12 weeks

These will be discussed with you by your healthcare professional when the treatment is offered.

Your podiatrist will discuss the benefits and risks of the procedure with you in more detail – please let them know if you have any questions or would like any further information.


Are there any alternatives?


If ESWT does not help your pain, then sometimes an injection option or operation may be available, depending on your condition. Your podiatrist will discuss this with you.


How can I prepare for ESWT?

You will need to be available for the full course of treatment. You should not take any non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, for two weeks before your first procedure, and throughout your treatment. If you are unsure if any of your medicines contain NSAIDs then please check with your podiatrist, doctor, nurse or pharmacist. Wear comfortable clothing as you will be lying on your front for the treatment.


Consent – asking for your consent


We want to involve you in decisions about your care and treatment. If you decide to go ahead, you will be asked to sign a consent form. This states that you agree to have the treatment and you understand what it involves. If you would like more information about our consent process, please speak to the podiatrist caring for you.

Who will carry out the procedure?


Your ESWT will be carried out by one of the podiatrists all of who have undertaken special training to carry out the procedure.


What happens during ESWT?

The treatment will be given in the podiatry clinic. You will be asked to lie on your front with your legs supported by a pillow. The clinician will put some ultrasound gel on the injured area and then place the hand piece of the device on the gel. The ESWT is delivered using this hand piece – it delivers compressed air pulses through the ultrasound gel. Each treatment will take approximately 20-30 minutes.


Will I feel any pain?


Most patients do experience some pain or discomfort during the procedure. You will be asked how much pain you are experiencing during the treatment, and we will try to adjust the treatment to help manage this.


What happens after ESWT?


After the treatment you will be able to get up and walk straight away. If you do experience discomfort following the shockwave treatment you can take over-the-counter painkillers (such as paracetamol) but don’t take anti-inflammatory medication (such as ibuprofen) or use ice therapy, as these can interfere with the body’s healing process.


What do I need to do after I go home?

You will be able to return to your usual activities, including returning to work, straight away.
However we advise you not to undertake any strenuous, pain-provoking activity or high-impact
exercise for 48 hours after the procedure.